Health & Wellness Blog - Page 62

GLP-1 Persistence for Weight Loss Nearly Doubles in Recent Years

Persistence rates for GLP-1 medications like semaglutide and tirzepatide in patients without diabetes seeking weight loss have nearly doubled over the past five years, jumping from 33.2% in 2021 to 60.9% in mid-2024. New research highlights improved adherence, the role of drug switching, and factors like resolved supply shortages driving these gains. These trends offer hope for long-term obesity management.

Shotlee·Mar 13, 2026·5 min read

GLP-1 Market News

Novo Crash Cuts Wegovy Maker Shareholder Assets by a Third

Novo Nordisk A/S's dramatic stock slump has reduced controlling shareholder Novo Holdings' assets by about a third to 694 billion Danish kroner ($108 billion). Facing cheaper copycats and Eli Lilly rivalry, the Wegovy maker confronts steep sales declines. Despite challenges, the fund posted 9% returns.

Shotlee·Mar 12, 2026·5 min read

GLP-1 Medications

Ozempic-Like Shots Curb 'Drug Noise' for Addicts: Insurance When?

GLP-1 drugs like Ozempic are silencing 'drug noise' in addicts, slashing overdoses and ER visits per a massive veterans study. Dr. Ziyad Al-Aly explains how these shots target brain reward systems. But FDA approval and insurance coverage remain years away—here's what patients need to know.

Shotlee·Mar 12, 2026·5 min read

GLP-1 Medications

Study: Ozempic-Type Drugs Like Semaglutide Can Be Made for $3/Month

A groundbreaking study shows blockbuster drugs like Ozempic and Wegovy could be manufactured at a fraction of their retail cost, potentially revolutionizing access to obesity and diabetes care. Researchers estimate semaglutide production at $3 per month for injectables, compared to hundreds today. This comes amid rising obesity in low-income countries, though experts stress lifestyle factors remain key.

Shotlee·Mar 12, 2026·4 min read

GLP-1 & Peptide Therapy

GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia

Emerging reports suggest GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) may trigger unusual sensory side effects, including painful skin sensitivity known as dysesthesia and allodynia. A new case series provides critical insights for patients and clinicians.

Shotlee·Mar 12, 2026·7 min read

GLP-1 Medications

Brianna LaPaglia's Ozempic Warning: 3 Pressures Behind Viral Claim

Influencer Brianna 'Chickenfry' LaPaglia's TikTok blast—'You're gonna die. You're all gonna die.'—targets Ozempic use among those who 'do not need' it, sparking viral debate. Page Six coverage highlights three colliding pressures amid Baptist Health's side effect warnings. Her personal recovery from disordered eating adds weight to the caution.

Shotlee·Mar 12, 2026·5 min read

Pharmaceuticals & Biotechnology

Eli Lilly Invests $3B in China for Next-Gen Oral GLP-1 Drug Production

Eli Lilly is set to invest a substantial $3 billion in China over the next decade to bolster the production of its groundbreaking oral GLP-1 receptor agonist, Orforglipron. This strategic move aims to enhance supply chain capacity for a drug poised to treat type 2 diabetes and obesity.

Shotlee·Mar 12, 2026·8 min read

GLP-1 Medications

CDSCO Advisory Curbs Misleading Promotion of GLP-1 Obesity Drugs

India's CDSCO has issued a strict advisory against misleading promotions of prescription obesity drugs like GLP-1 receptor agonists. The regulator targets indirect ads, exaggerated claims, and efforts undermining lifestyle changes. This move reinforces ethical marketing and patient safety in obesity treatment.

Shotlee·Mar 11, 2026·4 min read

Metabolic Health

Fat Cells Burn Energy for Heat: Next Weight Loss Frontier

Fat tissue isn't just storage—it's a dynamic organ that can burn energy as heat, opening new doors for weight loss beyond appetite-suppressing drugs like Ozempic and Wegovy. Researchers are targeting brown and beige fat to boost calorie burn without triggering hunger. This could be the next era in metabolic therapies.

Shotlee·Mar 11, 2026·4 min read

Latest Articles

Latest Articles

GLP-1 Persistence for Weight Loss Nearly Doubles in Recent Years

Novo Crash Cuts Wegovy Maker Shareholder Assets by a Third

Ozempic-Like Shots Curb 'Drug Noise' for Addicts: Insurance When?

Study: Ozempic-Type Drugs Like Semaglutide Can Be Made for $3/Month

GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia

Brianna LaPaglia's Ozempic Warning: 3 Pressures Behind Viral Claim

Eli Lilly Invests $3B in China for Next-Gen Oral GLP-1 Drug Production

CDSCO Advisory Curbs Misleading Promotion of GLP-1 Obesity Drugs

Fat Cells Burn Energy for Heat: Next Weight Loss Frontier

Latest Articles

GLP-1 Persistence for Weight Loss Nearly Doubles in Recent Years

Novo Crash Cuts Wegovy Maker Shareholder Assets by a Third

Ozempic-Like Shots Curb 'Drug Noise' for Addicts: Insurance When?

Study: Ozempic-Type Drugs Like Semaglutide Can Be Made for $3/Month

GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia

Brianna LaPaglia's Ozempic Warning: 3 Pressures Behind Viral Claim

Eli Lilly Invests $3B in China for Next-Gen Oral GLP-1 Drug Production

CDSCO Advisory Curbs Misleading Promotion of GLP-1 Obesity Drugs

Fat Cells Burn Energy for Heat: Next Weight Loss Frontier